Document Type
Article
Language
eng
Publication Date
1-2018
Publisher
American Society for Microbiology
Source Publication
Antimicrobial Agents and Chemotherapy
Source ISSN
0066-4804
Abstract
mecA-positive Staphylococcus aureus isolates phenotypically susceptible to cefoxitin (mecA-methicillin-sensitive S. aureus[MSSA]) have been identified. We describe the treatment and outcomes among patients with mecA-MSSA bloodstream infections (BSI) and MRSA BSI matched 1:1 for age, BSI origin, and BSI type (n = 17 per group). Compared to MRSA BSI patients, mecA-MSSA BSI patients more often experienced clinical failure (58.8% and 11.8%, P = 0.010), driven largely by persistent bacteremia (35.3% and 11.8%). mecA-MSSA BSI patients may be at higher risk for poor clinical outcomes.
Recommended Citation
Jones, Dylan; Elshaboury, Ramy; Munson, Erik; and Dilworth, Thomas J., "A Retrospective Analysis of Treatment and Clinical Outcomes among Patients with Methicillin-Susceptible Staphlococcus aureus Bloodstream Isolates Possessing detecable mecA by a Commercial PCR Assay Compared to Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates" (2018). Clinical Lab Sciences Faculty Research and Publications. 45.
https://epublications.marquette.edu/clinical_lab_fac/45
Comments
Published version. Antimicrobial Agents and Chemotherapy, Vol 62, No. 1 (January 2018): e01396-17. DOI. © 2017 American Society for Microbiology. Used with permission.